Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or ... MarketWatch (press release) In this study, inotuzumab ozogamicin was administered on a once-a-month schedule in combination with rituximab and compared with an active comparator arm (investigator's choice of bendamustine plus rituximab or gemcitabine plus rituximab). During a ... Pfizer halts study of non-Hodgkin's lymphoma drug Pfizer (PFE) says it's discontinuing Phase 3 studies on its investigational ... |
